In a report published Tuesday, Cantor Fitzgerald analyst Naved Khan reiterated a Buy rating on Priceline.com (NASDAQ: PCLN), and raised the price target from $800.00 to $900.00.

In a report published on Tuesday, Cantor Fitzgerald analyst Irina Rivkind upgraded the rating on Cubist Pharmaceuticals (NASDAQ: CBST) from Sell to Hold and raised the price target from $40 to $49.

NEW YORK (TheStreet) -- CHANGE IN RATINGS Cubist Pharmaceuticals was upgraded at Cantor Fitzgerald to hold from sell. Valuation call, based on a $49 price target, Cantor said. Carnival was downgraded at UBS to neutral from buy. The worst is not behind the company as bookings have gotten worse, UBS said. Price target goes to $36. ... Click to view ...

In a report published Wednesday, Cantor Fitzgerald analyst David Toti reiterated a Buy rating and $17,00 price target on CubeSmart (NYSE: CUBE). In the report, Toti noted, “Last week, we spent a few days on the road with the executive management team at CubeSmart, including Mr.

In a report published Wednesday morning, Cantor Fitzgerald analyst Irina Rivkind reiterated a Hold rating on Pernix Therapeutics (NASDAQ: PTX) and lowered the price target from $7 to $3.